Can Diabetics Take Glucosamine-Chondroitin?

Most people with diabetes can safely take glucosamine-chondroitin at standard oral doses without meaningful disruption to their blood sugar control. This answer might surprise you, because for years the concern was that glucosamine could worsen insulin resistance. That worry came from animal experiments using intravenous glucosamine at concentrations far above what an oral supplement produces in the bloodstream. When researchers actually tested the pills people buy at the drugstore, the results looked reassuringly different.

Where the Worry Came From

The fear that glucosamine could harm blood sugar started in the early 1990s with laboratory and animal research. When researchers infused glucosamine directly into the veins of rats, it caused severe insulin resistance in skeletal muscle, dramatically reducing the muscles’ ability to take up glucose in response to insulin.¹ In isolated muscle tissue, pre-exposure to glucosamine blocked insulin-stimulated glucose transport in a way that was both time- and dose-dependent.² Separate experiments found that glucosamine infusion also impaired the pancreas’s ability to secrete insulin in response to glucose, mimicking the beta-cell dysfunction seen in type 2 diabetes.³

The mechanism is biologically plausible. Glucosamine feeds into the hexosamine biosynthesis pathway, a sugar-processing route inside cells that helps regulate how the body senses nutrient status. When this pathway gets overloaded, it can reduce the activity of insulin-signaling proteins and impair the translocation of glucose transporters to the cell surface.⁴ More concerning still, chronic glucosamine exposure in pancreatic beta cells reduced their energy production and insulin output, possibly by damaging the cells’ energy-producing machinery.⁵

This is the body of evidence that prompted cautionary labels and nervous recommendations from clinicians throughout the 2000s. The biology looked alarming. But all of it involved either intravenous delivery or direct application of glucosamine to cells in a dish, and the concentrations used were far higher than what an oral supplement produces after passing through the gut and liver.

Why Oral Supplements Are Different

The single most important detail in this whole debate is bioavailability. When you swallow a 500-milligram glucosamine capsule, your digestive system and liver metabolize a large fraction of it before it ever reaches your bloodstream. The plasma concentrations achieved by a standard oral dose are a small fraction of the levels produced in those intravenous rat experiments. A randomized, placebo-controlled, crossover trial tested the standard regimen of 500 mg taken three times daily for six weeks in both lean and obese adults. Compared to placebo, oral glucosamine did not cause insulin resistance or worsen it in obese participants.⁶

This gap between intravenous and oral results is not unusual in pharmacology. Many substances are harmful when injected directly into the bloodstream at high doses but perfectly tolerable when eaten, because the gut and liver act as filters. For glucosamine, that filtering appears to be the decisive factor.

What the Clinical Data Shows for People With Diabetes

Beyond studies in people without diabetes, research has looked directly at whether glucosamine affects blood sugar in people who already have the disease. A study of patients with type 2 diabetes taking glucosamine-chondroitin for osteoarthritis found no significant worsening of glycemic control, as measured by hemoglobin A1c levels. The participants maintained excellent blood glucose management, with a mean glycohemoglobin of about 6.45%, and the supplement posed no meaningful risk to their diabetes management.⁷

Longer-term data from a trial in overweight and obese middle-aged women reinforced this. After two and a half years of glucosamine sulfate supplementation, with follow-up extending to six and a half years, there was no significant effect on HbA1c levels and no increase in the rate of new-onset diabetes. Even when the researchers separated out people who already had borderline-high HbA1c at the start, the results were the same.⁸

A clinical review synthesizing the available patient-oriented evidence concluded that glucosamine-chondroitin at typical doses (1,500 mg glucosamine / 1,200 mg chondroitin daily) does not adversely affect short-term glycemic control in patients whose diabetes is well-controlled.⁹ That same review flagged one caveat: some preliminary evidence suggested glucosamine could worsen glucose tolerance in people with untreated or undiagnosed glucose intolerance. The evidence for that concern was rated low quality, but it means the people most at risk from glucosamine may be those who do not know they have a blood sugar problem in the first place.

The Chondroitin Half of the Equation

Most of the debate focuses on glucosamine, but glucosamine-chondroitin supplements contain both compounds, and the chondroitin component deserves its own look. The news here is surprisingly positive. In a diabetic rat model, eight weeks of oral chondroitin sulfate treatment actually lowered blood glucose, increased body weight (the animals were wasting from uncontrolled diabetes), and improved bone mineral density.¹⁰

A recent preclinical study found that chondroitin sulfate profoundly lowered blood glucose in severely diabetic mice and improved glucose tolerance in diet-induced obese mice, without causing dangerously low blood sugar. The improvement appeared to involve increased insulin secretion and better insulin action.¹¹ Related animal work using a specialized form of chondroitin sulfate from sea cucumber showed it could decrease fasting blood glucose and improve liver glucose metabolism by modulating key metabolic enzymes and insulin signaling.¹²

These are animal findings, so we should not overinterpret them. But the pattern is consistent: chondroitin sulfate, far from posing a glucose risk, may nudge blood sugar in a favorable direction. At minimum, there is no evidence it worsens glycemic control. If anything, the chondroitin in a combination supplement may offset whatever marginal hexosamine-pathway effects glucosamine could theoretically have at oral doses.

A Potential Gut Microbiome Connection

An emerging line of research suggests glucosamine and chondroitin sulfate may influence blood sugar through the gut microbiome. A systematic review of animal and human studies found that the two supplements can alter the composition of gut bacteria. In animal models, those microbiome changes were associated with increased secretion of GLP-1, a gut hormone that stimulates insulin release and improves glucose tolerance.¹³ GLP-1 is the same hormone targeted by medications like semaglutide (Ozempic) and liraglutide, which are used to treat type 2 diabetes and obesity. The supplement doses used in these studies are unlikely to produce anything like the GLP-1 boost from those drugs, but the direction of the effect is intriguing and may partly explain why observational studies tend not to find glucose harm from glucosamine use.

Who Should Be More Cautious

The clinical evidence is generally reassuring, but a few groups warrant extra attention. As noted above, people with undiagnosed or untreated prediabetes may be the most vulnerable to any blood sugar effects from glucosamine, because their glucose regulation is already under strain and they are not receiving medication to compensate. If you are taking glucosamine-chondroitin and have not had your blood sugar checked recently, periodic monitoring is a reasonable precaution regardless of how unlikely harm appears.

People with very poorly controlled diabetes occupy a gray zone. Most clinical data involves participants whose diabetes was well-managed. Interestingly, the original rat study found that glucosamine infusion did not worsen insulin resistance in rats that were already severely hyperglycemic, possibly because the hexosamine pathway was already saturated by their high blood sugar.¹ Still, the clinical trial coverage for people with HbA1c values well above 8% is thin, and the long-term effects in this group remain unknown.

One animal study found no interaction between glucosamine and metformin, and glucosamine did not worsen insulin resistance in diabetic rats already on the drug.¹⁴ That is only one study in rats and should not be taken as proof of safety with every diabetes medication, but it is at least consistent with the broader pattern of oral glucosamine not disrupting glucose homeostasis.

The Warfarin Interaction That Actually Matters

For people with diabetes who are also on blood thinners, there is a drug interaction worth knowing about that has nothing to do with blood sugar. Case reports and a review of the FDA’s MedWatch database identified 20 reports of glucosamine or glucosamine-chondroitin use with warfarin associated with increased anticoagulation, showing up as elevated INR values or increased bleeding and bruising.¹⁵ Diabetes raises cardiovascular risk, so a meaningful number of people with diabetes take warfarin or similar anticoagulants. If you are among them, mention glucosamine-chondroitin to whichever clinician manages your anticoagulation, and expect more frequent INR monitoring when starting or stopping the supplement.

Cardiovascular Effects and Conflicting Signals

Some large observational studies have linked habitual glucosamine use with reduced cardiovascular risk. A prospective study from the UK Biobank found that glucosamine users had roughly a 15% lower risk of total cardiovascular events and about a 22% lower risk of cardiovascular death compared to non-users.¹⁶ A propensity score-matched cohort study found an 8% lower risk of coronary heart disease and an 8% lower risk of diabetes among regular glucosamine users over roughly 14 years of follow-up.¹⁷

However, a separate large study of nearly 686,000 osteoarthritis patients found the opposite: glucosamine use was associated with about a 10% higher risk of cardiovascular disease and a 12% higher risk of coronary heart disease. Those who used it most consistently had the highest risk, with a dose-response pattern.¹⁸ These are all observational studies, meaning the glucosamine users and non-users differed in many ways that statistical adjustments can only partially correct. People who take glucosamine tend to also take more supplements and anti-inflammatory drugs,¹⁹ which makes it hard to isolate glucosamine’s independent effect. For now, the cardiovascular picture is unresolved, and neither the protective nor the harmful finding should change whether you take the supplement.

Why Diabetes and Osteoarthritis Overlap

People with type 2 diabetes develop osteoarthritis at higher rates than the general population, and this is not just because both conditions are common in older adults. Chronic high blood sugar accelerates the formation of advanced glycation end products, which cross-link with collagen in cartilage, increasing its stiffness and promoting degradation.²⁰ Research in joint-lining cells has shown that hyperglycemia drives the accumulation of these glycation products, which then trigger inflammation and chondrocyte destruction.²¹ A 2025 review described this as the “AGE-collagen axis,” a plausible but not yet fully validated link between metabolic dysfunction and the structural breakdown seen in osteoarthritis.²²

This overlap means many people with diabetes have a genuine clinical need for joint pain relief, which makes the safety question around glucosamine-chondroitin especially relevant. For someone whose cartilage is already being degraded partly because of their diabetes, avoiding a potentially helpful supplement out of misplaced fear of blood sugar harm is a real cost. The irony is that the metabolic condition creating the need for joint support is the same one that has made people afraid to use it.

Practical Monitoring If You Decide to Take It

If you have diabetes and choose to start glucosamine-chondroitin, a simple monitoring plan can give you confidence. Check your fasting blood glucose and, if possible, your HbA1c before starting the supplement. Recheck your fasting glucose after two to four weeks and your HbA1c at your next routine lab draw, which for most people with diabetes is every three to six months. If your numbers stay stable, you can treat the supplement like any other part of your joint-health routine. If they drift upward, stop the supplement for a few weeks and see if they return to baseline, which will tell you whether the supplement was actually responsible.

Keep in mind that glucosamine supplements come in different salt forms. Glucosamine sulfate and glucosamine hydrochloride are the two most common, and most of the reassuring clinical data involves glucosamine sulfate. There is also N-acetyl glucosamine, which enters the hexosamine pathway at a slightly different point. Chondroitin sulfate formulations are more uniform. If you are looking to match what was studied in clinical trials, a product providing 1,500 mg of glucosamine sulfate and 1,200 mg of chondroitin sulfate daily is the standard regimen.

One thing worth noting: the supplement market is loosely regulated, and the actual content of glucosamine and chondroitin capsules can vary from what the label states. Choosing a product that has been independently tested by a third-party lab can reduce the risk of getting an underdosed or contaminated supplement, which matters for any supplement but perhaps especially when you are trying to keep a chronic condition well-managed.